ranolazine ER / Generic mfg. - LARVOL DELTA

Cardiologists' Diagnostic and Therapeutic Approaches in the Outpatient Management of Patients with Chronic Coronary Syndrome in Turkey: An Observational-Registration Study. (PubMed, J Cardiovasc Dev Dis) - "Medical therapy was the predominant management strategy for CCS in Turkey. The observed diagnostic and therapeutic patterns reflect real-world management of patients with established CCS, with substantial use of invasive coronary angiography and high baseline utilization of guideline-directed medical therapies."

Journal • Cardiovascular

Ranolazine inhibits invasiveness of human breast cancer cells in combination with a tyrosine kinase inhibitor: Dose-dependent synergy. (PubMed, J Pharmacol Exp Ther) - "Here, we aimed to test whether cotreatment of a model TNBC cell line, MDA-MB-231, with an epidermal growth factor receptor inhibitor (AG1478 [AG]) and RAN would produce a synergistic effect on invasiveness. These findings raise the possibility of treating triple-negative breast cancer nontoxically while reducing the chance of developing drug resistance. The results are also potentially applicable to multiple carcinomas."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR

Coronary Ectasia and Ventricular Arrhythmia in a Patient With Prior Tick Exposure and Borrelia burgdorferi IgG Seroreactivity: A Case Report. (PubMed, Cureus) - "Coronary ectasia with prolonged contrast retention should be recognized as a potential substrate for myocardial ischemia and ventricular arrhythmogenesis in patients without obstructive coronary artery disease. In selected patients with anginal symptoms and frequent ventricular ectopy, particularly when beta-blockers or conventional antiarrhythmic drugs are limited by bradycardia, QTc prolongation, or concern for conduction disease, ranolazine may offer a useful therapeutic option with combined antianginal and potential antiarrhythmic benefit."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Infectious Disease • Inflammatory Arthritis • Lyme Disease • Myocardial Ischemia • Pulmonary Disease • Vasculitis • Ventricular Tachycardia

Connexin-43 remodeling drives atrial arrhythmias in hypothyroidism: ranolazine as a potential therapeutic strategy. (PubMed, Biochem Pharmacol) - "Hypothyroidism was induced in Wistar rats with methimazole (0.02 % in drinking water) for 28 days. Overall, these findings demonstrate that hypothyroidism induces significant electrophysiological, structural and contractile atrial remodeling, resulting in increased susceptibility to atrial arrhythmia. These findings highlight the importance of thyroid hormone signaling in maintaining atrial electrical stability and suggest that targeting electrical instability with ranolazine may have therapeutic potential in hypothyroid cardiac remodeling."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • GJA1

The role of ranolazine in managing chronic coronary syndrome: a synthesis of clinical outcomes and health economic modelling (ESC 2026) - "Ranolazine effectively lowers the incidence of myocardial infarction (MI) and the demand for revascularisation while enhancing patients' quality of life, symptom control, and exercise capabilities. Offering both sustained cardiovascular benefits and strong cost-effectiveness, these results endorse the incorporation of ranolazine into standard CCS treatment protocols and broader healthcare resource strategies."

Clinical • Clinical data • HEOR • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Prophylactic ranolazine and trimetazidine attenuate right ventricular dysfunction and improve exercise capacity in experimental pulmonary hypertension (ESC 2026) - "Ranolazine additionally prevented adverse electrical remodeling. These findings support early metabolic intervention as a potential therapeutic strategy in PAH and warrant further clinical investigation."

Cardiovascular • Heart Failure

Unexplained Perivascular Chorioretinal Atrophy: Is Ranolazine a Possible Cause? (PubMed, J Ophthalmic Vis Res) - "Three months after drug cessation, the patient's visual field and electroretinogram improved. This is the first case report on ranolazine-associated chorioretinal toxicity, highlighting the necessity of further studies on potential side effects of even short-term exposure to this drug."

Journal • Cardiovascular

Protective Effects of Ranolazine in a Rat Model of Ovarian Ischemia/Reperfusion Injury. (PubMed, Int J Mol Sci) - "These findings suggest that preventive pretreatment with ranolazine attenuates experimental ovarian I/R injury through antioxidant and anti-inflammatory mechanisms. Future studies are needed to determine whether similar protective effects can be achieved when ranolazine is administered after ovarian torsion or following surgical detorsion."

Journal • Preclinical • Cardiovascular • Inflammation • Reperfusion Injury • IL1B • IL6 • PTGS2 • TNFA

Improvement of invasive microvascular indices following guideline-directed treatment of structural coronary microvascular dysfunction: a case report. (PubMed, Eur Heart J Case Rep) - "Continuous thermodilution performed in the left anterior descending artery revealed reduced coronary flow reserve (CFR 2.2) and elevated minimal microvascular resistance (798 WU), consistent with structural CMD.A structured, symptom-guided pharmacological optimization strategy was initiated, including statin therapy, angiotensin-converting enzyme inhibition, beta-blockade, calcium-channel blockade, and ranolazine.At 4-month follow-up, angina was markedly improved. Repeat invasive assessment in the same coronary territory demonstrated improvement of microvascular indices (CFR 3.8; minimal microvascular resistance 461 WU). This case illustrates that guideline-directed medical therapy for coronary microvascular dysfunction may be associated with both symptomatic improvement and objective changes in microvascular function."

Journal • Cardiovascular

Functional coronary vascular disease: endotype-based classification, diagnosis, and targeted management. (PubMed, Front Cardiovasc Med) - "Management should integrate endotype-specific pharmacologic therapies such as calcium channel blockers, nitrates, ranolazine, ACE inhibitors, and beta-blockers with non-pharmacologic interventions including lifestyle modification and overall cardiovascular risk reduction. Personalized, endotype-guided strategies targeting both pathophysiology and modifiable risk factors are essential to optimize symptom control, prevent disease progression, and reduce major adverse cardiovascular events in patients with ANOCA and INOCA."

Journal • Review • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Myocardial Infarction • Pulmonary Disease

Response to the Comment on "Intranasal Mucoadhesive Chitosan Microspheres of Ranolazine: Formulation, Design, and Pharmacokinetic Evaluation". (PubMed, J Pharm Sci) - No abstract available

Journal • PK/PD data

Comment on "Intranasal Mucoadhesive Chitosan Microspheres of Ranolazine: Formulation, Design, and Pharmacokinetic Evaluation". (PubMed, J Pharm Sci) - No abstract available

Journal • PK/PD data

Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin-dependent protein kinase IIδ in a murine model of acute doxorubicin-related cardiotoxicity. (PubMed, Br J Pharmacol) - "Inhibition of late INa protects cardiomyocytes from pathologic CaMKIIδ hyperactivation and impaired Ca2+ handling in the setting of acute DOX cardiotoxicity."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Oncology • CAMK2D • NAV1

The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets. (PubMed, Cureus) - "Accordingly, a group of therapies that increase mitochondrial calcium, such as sodium glucose-linked transporter 2 inhibitors and ranolazine, have been investigated as potential treatments in heart failure. A second group of emerging therapies targets oxidative stress by directly scavenging ROS (MitoQ and SS-31) and has also been studied for use in heart failure. Contemporary research developments propose an alternative approach to targeting oxidative stress by enhancing endogenous antioxidant capacity through the administration of nicotinamide adenine dinucleotide (NAD) precursors, thereby increasing intracellular NAD availability."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Endotype-guided medical therapy and symptom response in ANOCA. (PubMed, EuroIntervention) - "In this multicentre real-world registry, invasive coronary endotyping was associated with distinct pharmacological management patterns and differential changes in angina-related quality of life across ANOCA endotypes."

Journal • Cardiovascular

Ranolazine: An Antiarrhythmic and Cardioprotective Agent. (PubMed, Cardiol Rev) - "Also, when beta-blockers and/or calcium channel blockers fail to successfully control the symptoms, ranolazine pitches in as an important second-line agent. This is also true when these primary therapeutic agents produce hypotension or severe bradycardia, as ranolazine does not exert a vasoactive and hypotensive action, nor does it have a bradycardic effect, except for extremely rare instances."

Journal • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypotension • Myocardial Ischemia

Ranolazine is associated with attenuation of lipopolysaccharide-induced acute kidney injury via modulation of inflammatory, oxidative, and vascular markers. (PubMed, Toxicol Appl Pharmacol) - "RAN treatment significantly attenuated these alterations, reducing inflammation, oxidative stress, and apoptosis, tubular injury and tubular transport-related signaling while partially restoring vascular and hypoxia-related signaling. Prophylactic RAN attenuated inflammation, oxidative stress, and tubular injury while preserving renal function and modulating vascular and tubular pathways in sepsis-associated AKI, supporting its potential as an adjunctive therapeutic strategy."

Journal • Acute Kidney Injury • Infectious Disease • Inflammation • Nephrology • Oncology • Renal Disease • Septic Shock • CASP3 • FLT1 • HIF1A • HMOX1 • IL1B • KIM1 • LCN2 • NOS3 • SCNN1A • SIRT1 • TNFA

Effects of Different Doses of Ranolazine on SIRT1, APELA, and APL13 in a Rat MCAO Model. (PubMed, Curr Issues Mol Biol) - "These findings indicate that higher-dose ranolazine was not associated with neuroprotection under the conditions of this study. However, given the limited sample size, absence of infarct volume analysis, lack of neurological functional assessment, and absence of tissue-level molecular validation, further studies are required to clarify the biological significance and potential clinical relevance of the observed biomarker changes."

Journal • Preclinical • SIRT1

Ranolazine: established indications and emerging therapeutic potential (PubMed, G Ital Cardiol (Rome)) - "Although the aforementioned contexts require further evaluation in targeted clinical trials, in all these areas ranolazine's pharmacodynamic profile suggests clinical benefits. Overall, a review that integrates current recommendations with a critical analysis of emerging therapeutic frontiers lays the foundation for an increasingly personalized therapeutic approach."

Journal • Review • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders • Neuralgia • Oncology • Pain

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation. (PubMed, J Pharm Sci) - "Pharmacokinetic evaluation in New Zealand White rabbits demonstrated significantly increased systemic exposure and prolonged plasma residence of ranolazine compared with the pure drug, confirming effective avoidance of hepatic first-pass metabolism. Collectively, these findings support mucoadhesive chitosan microspheres as a promising intranasal delivery platform for ranolazine and highlight the potential of formulation-driven intranasal strategies for drugs limited by unfavourable oral pharmacokinetics."

Journal • PK/PD data

Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-elevation myocardial infarction and multivessel disease: A phase IIb multicenter, randomized, controlled and open label study (INaMICRON). (PubMed, Int J Cardiol) - "This trial will provide feasibility data and an estimate of the magnitude of microvascular modulation achievable with early ranolazine after STEMI, informing the design of larger outcome-oriented studies and future precision approaches to post-MI care."

Journal • P2b data • Cardiovascular • Myocardial Infarction

A Study of Ranolazine in ALS (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Swathy Chandrashekhar, MBBS | Trial completion date: May 2026 ➔ Jul 2028 | Trial primary completion date: May 2026 ➔ Jul 2028

HEOR • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders • CST3

Ranolazine Co-Crystal: Molecular Docking, Coformer Selection, In vitro, In vivo Pharmacokinetic Assesment in Rat Plasma. (PubMed, Curr Top Med Chem) - "The RP-HPLC method was found to be accurate, sensitive, linear and specific following ICH guidelines, with hydrochlorothiazide as the internal standard. This study demonstrated the potential of in silico screening for selecting appropriate co-formers to enhance the physicochemical properties of Ranolazine, and the co-crystals have shown potential for improved therapeutic outcomes. These results indicate that further preclinical and clinical investigations of Ranolazine co-crystals could effectively improve drug performance."

Journal • PK/PD data • Preclinical

MINOCA, ranolazine, and the challenge of phenotype-driven therapy. (PubMed, Int J Cardiol) - No abstract available

Journal

Successful Use of Ranolazine in SCN5A p.R222Q-Related Multifocal Ectopic Purkinje-Related Premature Contractions. (PubMed, J Cardiovasc Electrophysiol) - "Ranolazine may represent a useful mechanism-guided option for SCN5A-related MEPPC."

Journal • Cardiomyopathy • Cardiovascular